ライフサイエンスコーパス: prostaglandin J2

1 o-prostaglandin A2 and 15-deoxy-Delta(12,14)-prostaglandin J2.

2 PGD2 but low levels of 15-deoxy-delta(12,14)-prostaglandin J2.

3 ogenous PPARgamma ligand 15-deoxy-Delta12,14-prostaglandin J2.

4 the absence of exogenous 15-deoxy-Delta12,14-prostaglandin J2.

5 ally similar to prostaglandin J2 and Delta12-prostaglandin J2.

6 glitazone (10(-5) M), or 15-deoxy-delta12,14-prostaglandin J2 (10(-5) M) down-regulated androgen-stim

7 e cyclopentenone prostaglandin 15-deoxydelta-prostaglandin J2 (15 d-PGJ2) exerts potent anti-inflamma

8 nother PPAR-gamma2 agonist, 15-d delta-12,14-prostaglandin J2 (15-d deltaPGJ2), blocked TNF-alpha-ind

9 r (PPAR)-gamma agonists 15-deoxy-delta 12,14-prostaglandin J2 (15-d-delta 12,14-PGJ2) and troglitazon

10 ignaling lipid molecule 15-deoxy-delta 12,14 prostaglandin J2 (15-d-PGJ2) and confers cytoprotection

11 d 6) renal and urinary 15-deoxy-Delta(12,14)-prostaglandin J2 (15-d-PGJ2) levels increased.

12 28-oic acid (CDDO) and 15-deoxy-delta(12,14)-prostaglandin J2 (15-dPGJ2).

13 d two PPAR-gamma agonists, 15-deoxy-D(12,14)-prostaglandin J2 (15d-PGJ2) and troglitazone were used.

14 Although 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) at micromolar concentrations

15 e prostaglandin D2 metabolite 15-deoxy-delta prostaglandin J2 (15d-PGJ2) bind to PPAR-gamma and stimu

16 the naturally occurring 15-deoxy-Delta12, 14-prostaglandin J2 (15d-PGJ2) decreased phorbol 12-myrista

17 me-dependent increase in 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) formation, an endogenous inh

18 15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) is a bioactive prostanoid pr

19 15-Deoxy-Delta(12,14) prostaglandin J2 (15d-PGJ2) is a natural ligand for the

20 15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) is a reactive membrane lipid

21 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) is naturally produced in the

22 etic PPAR-gamma agonists 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) or troglitazone and ciglitaz

23 yclooxygenase (COX)-dependent cyclopentenone prostaglandin J2 (15d-PGJ2) plays a key role.

24 posure (>12 h) induced 15-Deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) synthesis.

25 15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) was the most potent prostagl

26 one and the prostanoid 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2), all inhibited VSMC prolifer

27 ndogenous PPARgamma ligand, 15d-Delta(12,14)-Prostaglandin J2 (15d-PGJ2), and a selective thiazolidin

28 urally occurring ligand, 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2), or members of a new class o

29 In this study, 15-deoxy-delta12,14-prostaglandin J2 (15d-PGJ2)-induced Hsp70 was purified f

30 J2 (Delta(12)-PGJ2), and 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2).

31 press PPAR-gamma, and 15-deoxy-Delta(12, 14)-prostaglandin-J2 (15d-PG-J2), a PPAR-gamma agonist, comp

32 15-deoxy-Delta 12,14- Prostaglandin J2 (15dPGJ2) inhibits Nuclear factor kappa

33 ycerol esters, namely, 15-deoxy-Delta(12,14)-prostaglandin J2-2-glycerol (15d-PGJ2-G), PGD2-G, PGE2-G

34 azolidinedione class, and the natural ligand prostaglandin J2 act as agonists for PPARgamma and inhib

35 of the PPARgamma ligand 15-deoxy-Delta12,14-prostaglandin J2, although the addition of exogenous lig

36 cyclopentenone prostaglandin 15-deoxy-Delta-prostaglandin J2, ameliorated lung injury in young, but

37 extent as the same concentrations of Delta12-prostaglandin J2 and 15-deoxy-Delta12, 14-prostaglandin

38 utral lipid metabolites, 15-deoxy-Delta12,14-prostaglandin J2 and 9-hydroxyoctadecanoic acids, and pe

39 polyunsaturated fatty acids, 15-deoxy-delta prostaglandin J2 and components of oxidized low-density

40 olite behaved chromatographically similar to prostaglandin J2 and Delta12-prostaglandin J2.

41 dicated that the PPARgamma ligands 15-deoxy- prostaglandin J2 and GW1929 as well as PA induced LA-N-5

42 ent of MCF-7 cells with 15-deoxy-Delta 12,14-prostaglandin J2 and immunoprecipitation with cyclin D1

43 The biological modifier delta12-prostaglandin J2 and related prostaglandins have been re

44 us activators, including 15-deoxy-delta12,14-prostaglandin J2 and the antidiabetic agent troglitazone

45 data suggest roles for 15-deoxy-Delta(12,14)-prostaglandin-J2 and lipoxin A4, both of which are poten

46 tural PPAR-gamma ligand (15-deoxy-Delta12,14-prostaglandin J2) and a PPAR-gamma activator (troglitazo

47 olvement of cyclooxygenase 2, 15-deoxy Delta-prostaglandin J2, and peroxisome proliferator-activated

48 zoladinedione drugs and 15-deoxy-Delta12, 14-prostaglandin J2, and potential differences in their fun

49 and increases of its product 15-deoxy Delta-prostaglandin J2 as well as cyclooxygenase 2/15-deoxy De

50 icosatetraenoic acid and 15-deoxy-Delta12,14-prostaglandin J2 can function as subtype-selective ligan

51 cin and the PPAR ligand, 15-deoxy-Delta12,14-prostaglandin J2 compared with single drug exposures on

52 ate prostaglandin D2 and 15deoxy delta(12-14)prostaglandin J2 concentrations, and was reversed by rep

53 azone, troglitazone, and 15-deoxy-Delta12,14-prostaglandin J2) decrease levels of beta-catenin.

54 lopentenone prostaglandins (CyPGs), Delta-12 prostaglandin J2 (Delta(12)-PGJ2), and 15-deoxy-Delta12,

55 delta 12-Prostaglandin-J2 (delta 12-PG J2) is a derivative of pro

56 2 as well as cyclooxygenase 2/15-deoxy Delta-prostaglandin J2-dependent activation of peroxisome prol

57 ury involves cyclooxygenase 2/15-deoxy Delta-prostaglandin J2-dependent activation of peroxisome prol

58 product is 12,13-dihydro-15-deoxy-Delta12,14-prostaglandin J2 (dihydro-15d-PGJ2).

59 653: ED50, 8 x 10(-8) M; 15-deoxy-delta12,14-prostaglandin J2: ED50, 2 x 10(-6) M; ciglitizone: ED50,

60 In contrast, the PPARgammaligand prostaglandin J2 had no effect on protein or mRNA levels

61 thiazolidinediones and 15-deoxy-Delta12, 14-prostaglandin J2 have been shown to bind to PPARgamma, i

62 mma with troglitazone or 15-deoxy-delta12,14-prostaglandin J2 in human monocyte-derived macrophages i

63 onstrate that the PPARgamma ligand, 15-deoxy-prostaglandin J2, induces endogenous HGF mRNA and protei

64 several prostanoids, of which 15-deoxy-delta-prostaglandin J2 is the most potent, as well as members

65 hane, isoliquiritigenin, 15-deoxy-Delta12,14-prostaglandin-J2, menadione, 1-Cl-2,4-dinitrobenzene, an

66 ihydroxyvitamin D3, or the PPARgamma ligands prostaglandin J2 or troglitazone did not affect the deve

67 Troglitazone (TGZ) and 15-deoxy-Delta(12,14)-prostaglandin J2 (PGJ2) are peroxisome proliferator-acti

68 ent adipogenic hormones, e.g. metabolites of prostaglandin J2 (PGJ2) bind and activate PPARgamma.

69 We show that prostaglandin J2 (PGJ2), an endogenous product of inflam

70 We previously showed that prostaglandin J2 (PGJ2), one of the endogenous products

71 azone, troglitazone, and 15-deoxy-Delta12,14-prostaglandin J2 (PGJ2)] do not enhance Na+ transport in

72 Plasma 15-deoxy-Delta12, 14-prostaglandin J2 (PGJ2, an endogenous PPAR-gamma agonist

73 agonists ciglitazone or 15-deoxy-Delta 12,14-prostaglandin J2 resulted in a concentration- and time-d

74 653, pioglitazone, and 15-deoxy-delta(12,14)-prostaglandin J2 showed only weak or no inhibition.

75 GH failed to inhibit 15-deoxy-Delta12, 14-prostaglandin-J2-stimulated gene transcription mediated

76 ed that PPARgamma, with its ligand, 15-deoxy-prostaglandin J2, strongly stimulates HGF promoter activ

77 king similarity of the metabolite to Delta12-prostaglandin J2, the only form among the J2 series whos

78 receptor-gamma agonist 15-deoxy-Delta12, 14-prostaglandin J2 to attenuate TNFalpha-induced insulin r

79 erent PPARgamma ligands (15-deoxy-Delta12,14-prostaglandin J2, troglitazone, and rosiglitazone) in ca

80 esolution lipid molecule 15-deoxy-Delta12,14-prostaglandin J2 was produced in response to B burgdorfe

81 of prostaglandin D2, and 15deoxy delta(12-14)prostaglandin J2 were high at 2 hours, decreased as infl

82 , 8-iso-prostaglandin A2, and 15-deoxy-Delta-prostaglandin J2) were measured in biopsies and their su

83 12-prostaglandin J2 and 15-deoxy-Delta12, 14-prostaglandin J2, whereas under the same conditions, pro